{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:52:53Z","timestamp":1787032373096,"version":"build-2736575974"},"reference-count":13,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Vasopressin has systemic vasoconstrictive yet pulmonary vasodilatory effects, making it an ideal agent for hypotension management in infants with congenital diaphragmatic hernia (CDH)\u2013associated pulmonary hypertension. The side effects of vasopressin in this population, such as hyponatremia, are understudied. This study aims to characterize the effect of vasopressin on sodium concentrations in infants with and without CDH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This was a retrospective review of patients who received vasopressin while admitted to a level IV neonatal intensive care unit. The primary outcome was the incidence of hyponatremia (blood sodium &amp;lt;135 mmol\/L) during vasopressin therapy. Secondary outcomes included time to hyponatremia, dose and duration of vasopressin, incidence of severe hyponatremia (blood sodium &amp;lt;125 mmol\/L), and hypertonic saline use. Both blood serum and blood gas sample sodium concentrations were used to compare CDH vs non-CDH patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The average difference between baseline and lowest blood sodium was significant for both CDH and non-CDH patients for all samples (p &amp;lt; 0.001). There was no significant difference in the primary outcome, nor in the secondary outcomes of time to hyponatremia or duration of vasopressin infusion. The average dose of vasopressin was higher in the CDH vs non-CDH group (p = 0.018). The incidences of severe hyponatremia and hypertonic saline use were greater in the CDH vs non-CDH group for patients who had blood serum sodium samples collected (p = 0.049 and p = 0.033, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>This study showed that severe hyponatremia occurred more frequently in CDH vs non-CDH patients. Extreme caution is necessary when managing total body sodium in patients with CDH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5863\/1551-6776-29.4.385","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T17:21:32Z","timestamp":1723569692000},"page":"385-390","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Hyponatremia in Infants on Vasopressin Therapy"],"prefix":"10.5863","volume":"29","author":[{"given":"Caitlin","family":"Hawkins","sequence":"first","affiliation":[{"name":"Department of Pharmacy (CH*), Nationwide Children\u2019s Hospital, Columbus, OH; *CH was a student at the time of this study"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Hemmann","sequence":"additional","affiliation":[{"name":"Division of Pharmacy (BH, TH), Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trina","family":"Hemmelgarn","sequence":"additional","affiliation":[{"name":"Division of Pharmacy (BH, TH), Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"12","key":"2024081321211458700_i2331-348X-29-4-385-b01","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1055\/s-0040-1712999","article-title":"Effect of vasopressin on systemic and pulmonary hemodynamics in neonates","volume":"38","author":"Budniok","year":"2021","journal-title":"Am J Perinatol"},{"issue":"6","key":"2024081321211458700_i2331-348X-29-4-385-b02","first-page":"430","article-title":"Use of vasopressin in neonatal intensive care unit patients with hypotension","volume":"22","author":"Ni","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2024081321211458700_i2331-348X-29-4-385-b03","article-title":"Use of vasopressin as rescue therapy in refractory hypoxia and refractory systemic hypotension in term neonates with severe persistent pulmonary hypertension-a prospective observational study [published online ahead of print December 21, 2022]","author":"Shah","journal-title":"Am J Perinatol"},{"key":"2024081321211458700_i2331-348X-29-4-385-b04","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.XPS.0000489147.17551.89","article-title":"Vasopressin in perioperative management of congenital diaphragmatic hernia: a case report","volume":"13","author":"Malikiwi","year":"2017","journal-title":"Ann Pediatr Surg"},{"key":"2024081321211458700_i2331-348X-29-4-385-b05","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40748-017-0045-1","article-title":"Congenital diaphragmatic hernia\u2013a review","volume":"3","author":"Chandrasekharan","year":"2017","journal-title":"Matern Health Neonatol Perinatol"},{"issue":"3","key":"2024081321211458700_i2331-348X-29-4-385-b06","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1213\/ANE.0000000000004324","article-title":"Update on congenital diaphragmatic hernia","volume":"131","author":"Chatterjee","year":"2020","journal-title":"Anesth Analg"},{"issue":"1","key":"2024081321211458700_i2331-348X-29-4-385-b07","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jpeds.2014.03.059","article-title":"Vasopressin improves hemodynamic status in infants with congenital diaphragmatic hernia","volume":"165","author":"Acker","year":"2014","journal-title":"J Pediatr"},{"issue":"3","key":"2024081321211458700_i2331-348X-29-4-385-b08","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/PCC.0b013e3182720473","article-title":"Hyponatremia during arginine vasopressin therapy in children following cardiac surgery","volume":"14","author":"Davalos","year":"2013","journal-title":"Pediatr Crit Care Med"},{"issue":"7","key":"2024081321211458700_i2331-348X-29-4-385-b09","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00467-009-1323-6","article-title":"New aspects in the pathogenesis, prevention, and treatment of hyponatremic encephalopathy in children","volume":"25","author":"Moritz","year":"2010","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"2024081321211458700_i2331-348X-29-4-385-b10","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1080\/14767058.2020.1757642","article-title":"Vasopressin for refractory persistent pulmonary hypertension of the newborn in preterm neonates\u2013a case series","volume":"35","author":"Mohamed","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"3","key":"2024081321211458700_i2331-348X-29-4-385-b11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0039-1700963","article-title":"Severe hyponatraemia associated with the use of arginine-vasopressin in two neonates with complex congenital heart disease","volume":"9","author":"Leister","year":"2020","journal-title":"J Pediatr Intensive Care"},{"issue":"6","key":"2024081321211458700_i2331-348X-29-4-385-b12","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.athoracsur.2019.06.053","article-title":"Safety and efficacy of vasopressin after Fontan completion: a randomized pilot study","volume":"108","author":"Bigelow","year":"2019","journal-title":"Ann Thorac Surg"},{"issue":"19","key":"2024081321211458700_i2331-348X-29-4-385-b13","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.3889\/oamjms.2019.558","article-title":"Prevalence and risk factors for hyponatremia in preterm infants","volume":"7","author":"Kiem Hao","year":"2019","journal-title":"Open Access Maced J Med Sci"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/4\/385\/3419139\/i2331-348x-29-4-385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/4\/385\/3419139\/i2331-348x-29-4-385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:41:50Z","timestamp":1738762910000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/4\/article-p385.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,13]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.4.385","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}